Suppr超能文献

玻璃体内注射疗法治疗糖尿病性视网膜病变:简要综述

Intravitreal therapy for the management of diabetic retinopathy: A concise review.

作者信息

Arora Atul, Morya Arvind K, Gupta Parul C, Menia Nitin K, Nishant Prateek, Gupta Vishali

机构信息

Teleophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, Punjab, India.

Department of Ophthalmology, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India.

出版信息

World J Exp Med. 2024 Dec 20;14(4):99235. doi: 10.5493/wjem.v14.i4.99235.

Abstract

Diabetic retinopathy (DR) is a serious microvascular complication of diabetes mellitus and may result in irreversible visual loss. Laser treatment has been the gold standard treatment for diabetic macular edema and proliferative diabetic retinopathy for many years. Of late, intravitreal therapy has emerged as a cornerstone in the management of DR. Among the diverse pharmacotherapeutic options, anti-vascular endothelial growth factor agents have demonstrated remarkable efficacy by attenuating neovascularization and reducing macular edema, thus preserving visual acuity in DR patients.

摘要

糖尿病视网膜病变(DR)是糖尿病严重的微血管并发症,可导致不可逆的视力丧失。多年来,激光治疗一直是糖尿病性黄斑水肿和增殖性糖尿病视网膜病变的金标准治疗方法。近年来,玻璃体内注射疗法已成为糖尿病视网膜病变治疗的基石。在各种药物治疗选择中,抗血管内皮生长因子药物通过减轻新生血管形成和减轻黄斑水肿,从而在糖尿病视网膜病变患者中保留视力,已显示出显著疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1852/11551706/2982348d3c44/99235-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验